2021
Workgroups MOD2
,Index
Workgroup cancer and immunity........................................................................................................................2
STA 02: Cancer and the genome..........................................................................................................................7
Sta 03: differences between cancer...................................................................................................................12
STA 04: Myeloid malignancies............................................................................................................................16
1
, WORKGROUP CANCER AND IMMUNITY
Question 1
- Patient 1: Atezolizumab
o Atezolizumab is the first PD-L1 inhibitor approved by the U.S. Food and Drug
Administration
o By blocking PD-L1 they will prevent inhibition few T-cells present
- patient 2: Pembolizumab/ nivolumab
o both inhibit PD-1/PD-L1
- patient 3: oncolytic virus therapy
o patient has a cold tumor-> not well recognized by immune system
because low mutation burden
o virus can infect tumor cells and kill them; via lysis when virus replicates
releases tumor antigens
2
, induces inflammation
o virus makes the tumor more visible for the immune system
o not toxic for healthy cells
- patient 4: Pembolizumab/ nivolumab
o The missing self would lead to apoptosis when recognized by lymphocytes however
when there is PD-1 or PD-L1 expressed
o Pembolizumab and nivolumab inhibit PD-1/ PD-L1-> apoptosis when recognized by
lymphocytes
- patient 5: Adoptive T cells
o T cells that are reactive to tumor can be collected from patient and multiplied
o Produce more T cells that fight against the antigen present in tumor
- patient 6: ipilimumab
o Treg; blocks activation of effector cells
o Treg expresses a lot of CTL4= target ipilimumab
blocks Treg activity
by blocking Treg -> effector cells not inhibited and can fight cancer
3
, o Ipilimumab can also eliminate Tregs from tumor
- patient 7: CAR T cells
o Most commonly used CAR T-cells target B-cell antigens
o Are not HLA restricted; can recognize antigens on surface B-cells
o Recognize extracellular antigens; cell surface antigens
o Lack of specific targets
o Issues with tissue infiltration
- patient 8: BCG vaccination
o specific for bladder cancer
o bacteria containing BCGV can kill tumor cell or via antigen presentation activate
immune system
o this infection wakes up immune system
- patient 9: HPV vaccination
4
Workgroups MOD2
,Index
Workgroup cancer and immunity........................................................................................................................2
STA 02: Cancer and the genome..........................................................................................................................7
Sta 03: differences between cancer...................................................................................................................12
STA 04: Myeloid malignancies............................................................................................................................16
1
, WORKGROUP CANCER AND IMMUNITY
Question 1
- Patient 1: Atezolizumab
o Atezolizumab is the first PD-L1 inhibitor approved by the U.S. Food and Drug
Administration
o By blocking PD-L1 they will prevent inhibition few T-cells present
- patient 2: Pembolizumab/ nivolumab
o both inhibit PD-1/PD-L1
- patient 3: oncolytic virus therapy
o patient has a cold tumor-> not well recognized by immune system
because low mutation burden
o virus can infect tumor cells and kill them; via lysis when virus replicates
releases tumor antigens
2
, induces inflammation
o virus makes the tumor more visible for the immune system
o not toxic for healthy cells
- patient 4: Pembolizumab/ nivolumab
o The missing self would lead to apoptosis when recognized by lymphocytes however
when there is PD-1 or PD-L1 expressed
o Pembolizumab and nivolumab inhibit PD-1/ PD-L1-> apoptosis when recognized by
lymphocytes
- patient 5: Adoptive T cells
o T cells that are reactive to tumor can be collected from patient and multiplied
o Produce more T cells that fight against the antigen present in tumor
- patient 6: ipilimumab
o Treg; blocks activation of effector cells
o Treg expresses a lot of CTL4= target ipilimumab
blocks Treg activity
by blocking Treg -> effector cells not inhibited and can fight cancer
3
, o Ipilimumab can also eliminate Tregs from tumor
- patient 7: CAR T cells
o Most commonly used CAR T-cells target B-cell antigens
o Are not HLA restricted; can recognize antigens on surface B-cells
o Recognize extracellular antigens; cell surface antigens
o Lack of specific targets
o Issues with tissue infiltration
- patient 8: BCG vaccination
o specific for bladder cancer
o bacteria containing BCGV can kill tumor cell or via antigen presentation activate
immune system
o this infection wakes up immune system
- patient 9: HPV vaccination
4
